Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.

Our Vision:

Delivering on our Promise

Develop and commercialize medicines with significant potential to improve cancer care

Leadership

Experience and passion to build a company focused on improving the lives of patients

Commitment

We are in this business because we believe we can make a difference. Read about our commitment to improving the lives of cancer patients and their loved ones.